logo
Share SHARE
FONT-SIZE Plus   Neg

MMRC And Synta Pharma Begin Ganetespib Clinical Trial In Multiple Myeloma

Synta Pharmaceuticals Corp. (SNTA) and the Multiple Myeloma Research Consortium or MMRC announced the start of a clinical trial evaluating ganetespib, a second generation Hsp90 inhibitor being developed by Synta Pharmaceuticals, as a single agent and in combination with the proteasome inhibitor bortezomib (VELCADE) for the treatment of relapsed multiple myeloma.

The trial, made possible by the funding up to $1 million by the Multiple Myeloma Research Foundation (MMRF), will be conducted through the MMRC. The MMRC is a consortium of sixteen world-renowned academic institutions and community centers whose mission is to accelerate the development of novel and combination treatments for patients with multiple myeloma by promoting and facilitating collaborative research between industry and academia.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Comedian Jerry Seinfeld has signed a new production deal with Netflix Inc. that will make the online video streaming service the exclusive home for his new comedic projects. As part of Seinfeld's exclusive deal with Netflix, twenty four brand new episodes of "Comedians in Cars Getting Coffee" will being streaming exclusively on Netflix in installments in late 2017. Food delivery startup DoorDash and courier service Postmates have joined with robotic delivery developer Starship Technologies for conducting commercial delivery trials over the next few weeks. With Starship's self-driving delivery robots, DoorDash will do the delivery tests in Redwood City, California, while Postmates' tests will take place in Washington, D.C. They will carry food orders ... Aiming to better prepare its employees, Delta Air Lines has decided to begin new diversity training for all of its flight crews after incidents of alleged discrimination against passengers, Bloomberg reported.
comments powered by Disqus
Follow RTT